NCT00097019View on ClinicalTrials.gov

A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed

PHASE2CompletedINTERVENTIONAL

Enrollment

53

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions

Ovarian Cancer

Interventions

DRUG

bevacizumab

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY